An episode of defibrination with bleeding following high dose Edinburgh Factor IX
(D.E.F.IX) replacement in a patient with haemophilia B undergoing knee joint replacement
is reported. We have also monitored plasma fibrinopeptide A levels in patients with
haemophilia B following ten standard doses of D.E.F.IX (15–20 u/kg) and have been
unable to document any change. Activation of the coagulation system, as previously
noted, appears to be related to the use of Factor IX concentrates in high doses.
Keywords
Factor IX concentrates - Fibrinopeptide A levels - Disseminated intravascular coagulation